Valeritas (NSDQ:VLRX) said today that its wearable insulin delivery device has launched in Italy. The Bridgewater, N.J.-based company inked an exclusive distribution deal with Movi SpA to bring its V-Go device to the more than 2 million people in Italy with Type 2 diabetes. Get the full story at our sister site, Drug Delivery Business News.
Dexcom wins CMS nod for latest glucose monitor
Dexcom (NSDQ:DXCM) said today that its G6 continuous glucose monitoring system will be covered for Medicare beneficiaries. The company’s product won coverage as a therapeutic CGM system, making it available to beneficiaries who closely manage their insulin dosing. Get the full story at our sister site, Drug Delivery Business News.
Abbott CEO on Libre: ‘We’re just getting started’
Abbott (NYSE:ABT) posted its third quarter financial results yesterday, meeting its own forecast and the consensus set by analysts on Wall Street. The healthcare giant also narrowed its earnings outlook for the rest of the year. Abbott noted particularly high gains in revenue for its medical device division – sales were up 8.4% to $2.82 billion, in part […]
Anthem, Novo Nordisk team up for real-world diabetes drug study
Anthem’s outcomes research unit, HealthCore, and Novo Nordisk (NYSE:NVO) have joined forces to study Novo Nordisk’s semaglutide GLP-1 receptor agonist in people with Type 2 diabetes. The real-world trial is designed to compare the long-term effectiveness of the drug, also known as Ozempic, against 40 other medications among 2,250 adults with Type 2 diabetes. Get the full story […]
Valeritas aims for $50m in stock offering
Valeritas (NSDQ:VLRX) said this week that it plans to offer 37,593,984 shares of its common stock, hoping to raise $50 million in gross proceeds. The medical technology company also announced its preliminary financial results this week for the third quarter of 2018. Get the full story at our sister site, Drug Delivery Business News.
Valeritas shares fall despite Street-beating Q3 prelims
Shares in Valeritas (NSDQ:VLRX) fell today after the medical technology company announced its preliminary financial results for the third quarter of 2018. The Bridgewater, N.J.-based company said it expects to post quarterly revenue of approximately $6.9 million, just ahead of the $6.85 million predicted by analysts. Compared to the same period in 2017, Valeritas’ sales are up […]
Tandem wins approval for insulin pump in Canada
Tandem Diabetes Care (NSDQ:TNDM) won a medical device license from Health Canada last week for its t:slim X2 insulin pump. The device integrates directly with Dexcom‘s (NSDQ:DXCM) G5 continuous glucose monitor and is the only system of its kind approved in Canada, according to the San Diego, Calif.-based company. Get the full story at our sister site, […]
Canada clears Medtronic’s MiniMed 670G insulin pump
Medtronic‘s (NYSE:MDT) Canada subsidiary said today that it won a license from Health Canada for its MiniMed 670G insulin pump system. The insulin pump system is the first device in Canada that stabilizes glucose levels by automatically adjusting basal insulin delivery according to a user’s real-time needs, the medtech titan touted. Get the full story […]
Philips’ HealthSuite will track Ypsomed’s connected self-medication devices
Philips and Ypsomed said today that they will jointly develop a solution for Ypsomed’s new self-medication adherence monitoring services based on Philips’ HealthSuite digital platform. The combination of Ypsomed’s connected devices and Philips’ (NYSE:PHG) cloud-based digital platform will allow Ypsomed’s pharmaceutical customers to deliver value-added services aimed at improving patient outcomes, the companies said in a joint statement. […]
GI Dynamics eyes 2019 EU market return for EndoBarrier
GI Dynamics (ASX:GID) said yesterday that it tapped a new notified body in Europe, nearly a year after losing CE Mark approval there, as it eyes a market return for its EndoBarrier device by the end of next year. In the European Union, notified bodies are used as part of the regulatory system to assess product […]
Genentech kicks off Phase III trials for eye implant
Roche‘s (OTC:RHHBY) Genentech reported this week that the company launched three Phase III trials evaluating the Port drug-delivery implant in patients with wet age-related macular degeneration and diabetic macular edema. The device is a refillable eye implant designed to continuously release drugs over a period of several months. Get the full story at our sister site, Drug […]
- 1
- 2
- 3
- …
- 71
- Next Page »
MassDevice Network
@MassDevice
LinkedIn